ReviewFrontiers in cellular and infection microbiology2021
The Research Progress in Immunotherapy of Tuberculosis.
Review in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 36 citations in OpenAlex.
- Integration of transcriptome and mendelian randomization elucidates the protective role of aspirin in pulmonary tuberculosis development.Functional & integrative genomics · 2026Article
- Immunotherapy for tuberculosis: emerging modalities, cross-disciplinary innovations, and roadmaps for drug-resistant disease.Frontiers in immunology · 2026Review
- Stepwise PEG Precipitation Coupled with Hydrophobic Interaction Chromatography Enables the Production of Highly Specific Anti-Ag85B IgY for Tuberculosis Immunodiagnostics.Infection and drug resistance · 2026Article
- Efficacy ofFrontiers in medicine · 2026Article
- EP9158H: An Immunoinformatics-Designed mRNA Vaccine Encoding Multi-Epitope Antigens and Dual TLR Agonists for Tuberculosis Prevention.Bioengineering (Basel, Switzerland) · 2025Article
- Expression and clinical significance of peripheral blood NK cell surface co-signaling molecules in active pulmonary tuberculosis patients.BMC infectious diseases · 2025Article
- IFN-γ and IL-17 elicit synergistic anti-mycobacterial responses by inhibiting coronin-1A retention.Communications biology · 2025Article
- Immunotherapy for tuberculosis: current strategies and future directions.Military Medical Research · 2025Review
- Treatment outcomes and associated influencing factors among elderly patients with rifampicin-resistant tuberculosis: a multicenter, retrospective, cohort study in China.BMC infectious diseases · 2025Article
- Cell therapies for viral diseases: a new frontier.Seminars in immunopathology · 2025Review
- Dysregulation of the JNK signaling pathway in tuberculosis: mechanisms and therapeutic strategies.Frontiers in cellular and infection microbiology · 2025Review
- Article
- Enhanced Immune Responses AgainstIndian journal of microbiology · 2024Article
- Distinguish active tuberculosis with an immune-related signature and molecule subtypes: a multi-cohort analysis.Scientific reports · 2024Article
- The advances in adjuvant therapy for tuberculosis with immunoregulatory compounds.Frontiers in microbiology · 2024Review
- The progress ofFrontiers in medicine · 2024Review
- IFNγ-secreting T cells that highly express IL-2 potently inhibit the growth of intracellularFrontiers in immunology · 2024Article
- Review
- Advanced drug delivery and therapeutic strategies for tuberculosis treatment.Journal of nanobiotechnology · 2023Review
- Immunotherapy and biomarkers in patients with lung cancer with tuberculosis: Recent advances and future Directions.iScience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) is a serious public health problem worldwide. The combination of various anti-TB drugs is mainly used to treat TB in clinical practice. Despite the availability of effective antibiotics, effective treatment regimens still require long-term use of multiple drugs, leading to toxicity, low patient compliance, and the development of drug resistance. It has been confirmed that immune recognition, immune response, and immune regulation of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.